ARTICLE | Clinical News
APC8024: Began Phase I testing
January 16, 2001 8:00 AM UTC
Dendreon Corp. (DNDN), Seattle, Wash. Product: APC8024 Business: Cancer Therapeutic category: Immune stimulation Target: Immune cells Description: Engineered antigen that recruits immune cells agains...